Addition of oxaliplatin to standard lymphodepleting chemotherapy regimens should also be explored, as addition of oxaliplatin to cyclophosphamide in a murine model of lung cancer was shown to promote CAR-T cell recruitment to tumors via stimulation of chemokine secretion by macrophages and also improved antitumor immune responses when paired with anti-PD-L1 antibodies [194]. This evidence concerns the gene CD274 and lung cancer.